1. Market Research
  2. > Pharmaceutical Market Trends
  3. > WhanIn Pharmaceutical Co., Ltd. (ASMB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

WhanIn Pharmaceutical Co., Ltd. (WhanIn Pharma) is a specialty pharmaceutical company. It undertakes the development, manufacturing, marketing, and selling of therapeutic products. The company’s product portfolio includes a wide range of antiasthmatics, antidepressants, anxiolytics and hypnotics, nootropics, gastrointestinal drugs, cardiovascular drugs, anti-inflammatory analgesics, antibiotics, multi-vitamins and antifungals, among others. WhanIn Pharma has other pipeline products under development for the treatment of asthma, stroke, obesity, dementia and Hepatitis C. It also provides technology such as phellinus linteus KCTC0912BP, a producer of polysaccharides with anticancer activity. The company has partnerships with companies such as Shire, UCB , Lundbeck A/S, Egis, Gador, Doetsch Grether AG, Sandoz, and Abbott, among others. WhanIn Pharma is headquartered in Seoul, Gyeonggi-do, Korea.

WhanIn Pharmaceutical Co., Ltd. (ASMB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table Of Contents

WhanIn Pharmaceutical Co., Ltd. (ASMB) - Pharmaceuticals and Healthcare - Deals and Alliances Profile
Table of Contents


Table of Contents 2

List of Tables
3

List of Figures
4
WhanIn Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 5
WhanIn Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare Deals By Type, 2009 to YTD 2015 6
WhanIn Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 7
WhanIn Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8
WhanIn Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare, Deals Summary, 2009 to YTD 2015 9
WhanIn Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare, Deal Details 10
Partnerships 10
Abbott Enters Into Distribution Agreement With WhanIn For Depakote 10
Novartis Enters Into Distribution Agreement With WhanIn For Clozaril 11
WhanIn Pharma Enters Into Co-Promotion Agreement With Sandoz 12
Lundbeck Enters Into Distribution Agreement With WhanIn For Nalmefene 13
Acquisition 14
Truston Asset Management Acquires 5.22% Stake In WhanIn Pharma 14
WhanIn Pharmaceutical Co., Ltd. - Key Competitors 15
Key Employees 16
Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18


List of Tables

WhanIn Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare, Key Facts, 2013 1
WhanIn Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 5
WhanIn Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare Deals By Type, 2009 to YTD 2015 6
WhanIn Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 7
WhanIn Pharmaceutical Co., Ltd., Deals By Therapy Area, 2009 to YTD 2015 8
WhanIn Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare, Deals Summary, 2009 to YTD 2015 9
Abbott Enters Into Distribution Agreement With WhanIn For Depakote 10
Novartis Enters Into Distribution Agreement With WhanIn For Clozaril 11
WhanIn Pharma Enters Into Co-Promotion Agreement With Sandoz 12
Lundbeck Enters Into Distribution Agreement With WhanIn For Nalmefene 13
Truston Asset Management Acquires 5.22% Stake In WhanIn Pharma 14
WhanIn Pharmaceutical Co., Ltd., Key Competitors 15
WhanIn Pharmaceutical Co., Ltd., Key Employees 16


List of Figures

WhanIn Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 1
WhanIn Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 1
WhanIn Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 1
WhanIn Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare, Deals By Therapy Area, 2009 to YTD 2015 1
WhanIn Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 5
WhanIn Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 6
WhanIn Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 7
WhanIn Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8

Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • July 2016
  • by Global Markets Direct

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016’, ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.